Spotlight Therapeutics: Building programmable CRISPR platform, Spotlight aims at cancer targets with $36.5M series B

MAR 22, 2022 | 4:34 AM PDT | BIOCENTURY | FINANCEBUILDING PROGRAMMABLE CRISPR PLATFORM, SPOTLIGHT AIMS AT CANCER TARGETS WITH $36.5M SERIES BBY GV-backed, Bay Area biotech focusing on immuno-oncology for internal gene editing pipeline while mulling partnerships elsewherehttps://www.biocentury.com/article/642759/building-programmable-crispr-platform-spotlight-aims-at-cancer-targets-with-36-5m-series-b© 2022 BioCentury Inc. All Rights Reserved